Popular Articles

What Is Post Traumatic Stress Disorder? What Is PTSD? What Causes PTSD?
PTSD (Post-Traumatic Stress Disorder) is triggered by a traumatic event - it is a kind of anxiety. The sufferer of PTSD may have experienced or seen an event that caused extreme fear, shock and/or a feeling of helplessness. Most of us experience a brief period of difficulty adjusting and coping with traumatic events. However, we gradually get better with time and healthy coping methods. On the other hand, there are times when symptoms get worse and may last for several months, or years. This study explains how PTSD can surface two years after a traumatic event. Another study found that one in eight Lower Manhattan residents likely had PTSD two to three years after the 9/11 attacks.

Pioneering Research Into Healing Power Of Sugar
A pioneering University of Wolverhampton lecturer has won a ÷£25,000 grant to research the healing effect of sugar on cuts and wounds.
News of the day
Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine And Epinephrine Is Effective In Reducing Pain
Dharma Therapeutics, Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu Group Limited, a company listed on the Singapore Exchange Limited) announced that its improved active transdermal delivery technology, which administers lidocaine and epinephrine through the skin via a mild electric current, has demonstrated safety and efficacy in a Phase 2 clinical trial.
Diagnostics

Prenatal Malaria Exposure Increases Risk Of Malaria And Anemia For Some Children

Some babies who are exposed to malaria before birth develop a tolerant phenotype that increases their susceptibility to malaria and anemia in childhood, says a new study in the open access journal PLoS Medicine. Indu Malhotra and Christopher King (Case Western Reserve University) and colleagues studied 586 newborns residing in a malaria-holoendemic area of Kenya to age three, assessing their malaria infection, malaria-specific immune responses, and anemia, and classifying them into three groups: "sensitized" babies in which cord blood cells made activating cytokines in response to malaria antigens; "exposed, not-sensitized" babies in which cord blood cells did not make activating cytokines but made an inhibitory cytokine (IL-10); and "not-exposed" babies born to uninfected mothers. The authors report that in the first 3 years of life, the exposed, not-sensitized newborns had a 60% greater risk of malaria infection than the unexposed group and a slightly higher risk of malaria infection than the sensitized group. They also had lower hemoglobulin levels, a sign of anemia, than the other babies. At 6 months, the T-cells of exposed, not-sensitized children were less likely to make activating cytokines in response to malaria antigens but made more IL-10 than the T-cells of the other children; malaria-specific antibody levels were similar in the three groups, say the authors. Why some children exposed to malaria before birth become tolerant to the disease while exposure to malaria antigens "primes" the immune system of other children to respond efficiently to malaria antigens is not clear. However, these findings could have important implications for the design of malaria vaccines for use in areas where children are often exposed to malaria before birth and for the design of strategies for the prevention of malaria during pregnancy, say the authors. "Once the significance of fetal malaria experience is better understood," the authors say, "it should translate into more effective strategies for malaria chemoprophylaxis during pregnancy." In a related Perspective on the study, Lars Hviid (not involved in the research) states that the research by Dr. King and colleagues "adds significantly to our understanding of prenatal exposure to P. falciparum antigens" and has "obvious clinical importance." But he outlines several areas for further investigation of pregnancy-associated malaria. Funding: The work was supported in part by United States Public Health Service grants I064687, AI054711, MH080601, AI065717 and Veterans" Affairs Research Service. The funders had no role in the study design, data collection, analysis, decision to publish or preparation of the manuscript. They did contribute to the design of the study. Competing Interests: David Narum has declared the following competing interest: ""Narum et al., United States Patent 7,078,507 for production of recombinant EBA-175 RII protein."" Citation: "Can Prenatal Malaria Exposure Produce an Immune Tolerant Phenotype?: A Prospective Birth Cohort Study in Kenya." Malhotra I, Dent A, Mungai P, Wamachi A, Ouma JH, et al. (2009) PLoS Med 6(7): e1000116. doi:10.1371/journal.pmed.1000116 PLoS Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):